Eyenovia reported a second quarter net loss of $5.3 million, or $0.44 per share, compared with a net loss of $3.3 million, or, $0.33 per share, at the same time last year, according to a press release.
Research and development expenses increased from $2.4 million in the second quarter of 2018 to $3.6 million in the second quarter of 2019, which was attributed to the continuing advancement of the company’s clinical drug pipeline.
General and administrative expenses doubled from $0.9 million in 2018 to $1.8 million.
The company reported cash (Read more...)
Uncategorized